FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
December 18, 2025
Foley Viewpoints
NAIC Issues Statement Regarding AI Executive Order
On December 16, 2025, the National Association of Insurance Commissioners (NAIC) issued a statement (the NAIC Statement), on the December…
December 18, 2025
Foley Viewpoints
How Companies Can Roll with NY's New Algorithmic Pricing Rules
States are racing to rein in the growing use of artificial intelligence and computer algorithms to set prices, with New York leading the charge. On Dec. 15, a major amendment to New York's antitrust law took effect, banning the use of certain algorithmic rent-setting tools for residential units under Section 340-b of the state's General Business Law.
December 18, 2025
Foley Viewpoints
Texas Adopts the Uniform Interstate Depositions and Discovery Act
The Uniform Interstate Depositions and Discovery Act (“UIDDA”), which provides procedures for interstate discovery at the state-court level, has been adopted by nearly every state and territory. Texas’ status as one of the last holdouts to adopt the UIDDA has finally come to an end.